Pharmacogenomic research in imaging: The overarching goal is to investigate the role of genetic variation in disordered brain function using neuroimaging and biomarkers as phenotypes and to identify potential surrogate biomarkers for therapeutic trials. Major approaches include the development and application of state-of-the-art computational and informatics methods and tools for independent and combined analyses of the following multi-modal, heterogeneous imaging, genetics, and other biomarker data: (a) Imaging modalities: MRI (structural, fMRI, DTI, PASL, MRSI), PET; (b) Other measures: CSF and blood biomarkers, neuropsychological assessments; (3) Genetic variation: GWAS (SNP, CNV), pathways, targeted sequencing. The disorders we are investigating include Alzheimer's disease and mild cognitive impairment, breast cancer (neurocognitive effects of chemotherapy and hormonal interventions), mild traumatic brain injury, schizophrenia and other conditions.
Research and training being done at IU Center for Neuroimaging (CfN): (1) Utilize advanced imaging technologies to further the understanding of brain structure & function through the study of healthy individuals, clinical populations, and translational animal models. (2) Investigate the influence of genetic variation on imaging phenotypes including brain structure and function in health and illness as well as treatment response. (3) Provide training and experience in structural, functional and molecular neuroimaging research. (4) Develop, assess, and validate emerging technologies: optimize the use of existing molecular and functional imaging methodologies including PET, fMRI, DTI, MRS, perfusion and morphometric imaging; and develop advanced image processing and analytic methods to address emerging neuroscience questions. (5) Advance the state of the art in clinical care for brain disorders including neurosurgical planning and image-guided therapy.
More details are available at http://neuroimaging.medicine.iu.edu/.